Ergothioneine Microcapsule with Prebiotic Coating for Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Consuming mushrooms to obtain ergothioneine is inconvenient due to the need for large quantities, gastrointestinal discomfort, and potential adverse effects for kidney and gout patients, as well as nutrient loss if not cooked properly.
Innovation Solution
A microcapsule structure with a core layer of mushroom fruiting body particles and a coating layer containing polysaccharides, polyphenols, and ergothioneine, where the coating layer is formed by spraying a concentrated liquid on the core layer, increasing the content and bioavailability of these active ingredients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If large quantities of mushrooms are consumed to obtain sufficient ergothioneine, then the ergothioneine concentration is improved, but gastrointestinal discomfort and burden on the stomach increase
Solution Approach 1:
The patent extracts and isolates ergothioneine from mushroom cells through enzymatic digestion of cell walls, then encapsulates it in microcapsules. This separates the active ingredient from the bulk mushroom material that causes gastrointestinal discomfort, allowing high ergothioneine concentration without the harmful effects of consuming large quantities of whole mushrooms.
Solution Approach 2:
The patent changes the physical and chemical parameters of ergothioneine by removing it from its natural cellular environment, concentrating it into microcapsules with controlled release properties. This transforms the delivery mechanism from bulk mushroom consumption to concentrated microcapsule ingestion, improving concentration while reducing gastrointestinal burden.
2Quantity of substance
If large quantities of mushrooms are consumed to obtain sufficient ergothioneine, then the ergothioneine concentration is improved, but the burden on the stomach increases
Solution Approach 1:
The patent extracts and isolates ergothioneine from mushroom cells through enzymatic digestion of cell walls, then encapsulates it in microcapsules. This separates the active ingredient from the bulk mushroom material that causes gastrointestinal discomfort, allowing high argothioneine concentration without the harmful effects of consuming large quantities of whole mushrooms.
Solution Approach 2:
The patent changes the physical and chemical parameters of ergothioneine by removing it from its natural cellular environment, concentrating it into microcapsules with controlled release properties. This transforms the delivery mechanism from bulk mushroom consumption to concentrated microcapsule ingestion, improving concentration while reducing gastrointestinal burden.
3Quantity of substance
If mushrooms are taken to obtain ergothioneine, then the active ingredient is improved, but nutrient loss occurs if not cooked properly
Solution Approach 1:
The patent performs preliminary extraction and encapsulation of ergothioneine before consumption, preserving the nutrient in a stable microcapsule form. This eliminates the need for proper cooking preparation, as the ergothioneine is already isolated and protected from degradation during food preparation processes.
Solution Approach 2:
The patent changes the physical state of ergothioneine from its natural form in fresh mushrooms to an encapsulated form that is resistant to thermal degradation. This parameter change preserves the nutrient through various food preparation methods, preventing loss that would occur with improper cooking of fresh mushrooms.
4Quantity of substance
If mushrooms are consumed to obtain ergothioneine, then the active ingredient is improved, but high potassium content is not suitable for kidney patients and gout patients
Solution Approach 1:
The patent extracts and isolates ergothioneine from mushroom cells, separating it from other mushroom components including potassium. The resulting microcapsules contain purified ergothioneine with minimal accompanying minerals, making the supplement suitable for kidney and gout patients who need to limit potassium intake while still benefiting from ergothioneine supplementation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microcapsule structure enhances the bioavailability and absorption of ergothioneine and other active ingredients, reducing the need for large mushroom consumption and minimizing gastrointestinal discomfort, while being suitable for patients with kidney or gout issues.
Implementation Method 1
the coating layer is formed by spraying concentrated liquid on all or a part of surfaces of the core layer and the holes
Implementation Method 2
the core layer is obtained by freeze-drying
Data Source
AI summary
An ergothioneine microcapsule structure with prebiotics has a core layer and at least a coating layer, and the core layer has multiple holes. All of the holes are connected to each other, or all of the holes are not connected to each other, or a part of the holes are connected to each other, or a part of the holes are not connected to each other. The coating layer is formed by spraying concentrated liquid on all or a part of surfaces of the core layer and the holes. The concentrated liquid comprises prebiotics, such as polysaccharide, polyphenols and ergothioneine, and the core layer is formed by mushroom fruiting body particles. The present disclosure also illustrates a manufacturing method of the ergothioneine microcapsule structure with prebiotics, a usage of the ergothioneine microcapsule structure with prebiotics, and an oral dosage form of the ergothioneine microcapsule structure with prebiotics.